NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme Inc (NASDAQ:EPZM) issued its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.11. The biopharmaceutical company had revenue of $5.72 million for the quarter, compared to analyst estimates of $5.50 million. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. View Epizyme's Earnings History.

Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Epizyme.

Epizyme updated its third quarter earnings guidance on Wednesday, October, 30th. The company provided EPS guidance of -$0.40 for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.48). The company issued revenue guidance of $5.7 million, compared to the consensus revenue estimate of $6.40 million.

9 Wall Street analysts have issued 12-month target prices for Epizyme's shares. Their forecasts range from $18.00 to $36.00. On average, they expect Epizyme's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price. View Analyst Price Targets for Epizyme.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Headlines about EPZM stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Epizyme earned a daily sentiment score of 1.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Epizyme.

Epizyme saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,780,000 shares, an increase of 9.5% from the December 15th total of 8,020,000 shares. Based on an average daily trading volume, of 921,800 shares, the short-interest ratio is presently 9.5 days. Approximately 11.5% of the company's shares are short sold. View Epizyme's Current Options Chain.

Some companies that are related to Epizyme include Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Horizon Therapeutics (HZNP), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Reata Pharmaceuticals (RETA), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR) and Evotec (EVTCY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Nektar Therapeutics (NKTR), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Verastem (VSTM), Clovis Oncology (CLVS), Omeros (Omer), TG Therapeutics (TGTX), Amarin (AMRN) and Incyte (INCY).

Epizyme's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.47%), Woodstock Corp (0.05%), Perigon Wealth Management LLC (0.01%) and Vigilant Capital Management LLC (0.00%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros and Robert B Bazemore. View Institutional Ownership Trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros and Robert B Bazemore. View Insider Buying and Selling for Epizyme.

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Woodstock Corp, Perigon Wealth Management LLC and Vigilant Capital Management LLC. View Insider Buying and Selling for Epizyme.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EPZM stock can currently be purchased for approximately $22.40.

Epizyme has a market capitalization of $2.04 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

The official website for Epizyme is http://www.epizyme.com/.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]